185 related articles for article (PubMed ID: 28793914)
1. Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank.
Cadzow M; Merriman TR; Dalbeth N
Arthritis Res Ther; 2017 Aug; 19(1):181. PubMed ID: 28793914
[TBL] [Abstract][Full Text] [Related]
2. Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank.
Narang RK; Topless R; Cadzow M; Gamble G; Stamp LK; Merriman TR; Dalbeth N
Arthritis Res Ther; 2019 Jan; 21(1):13. PubMed ID: 30626429
[TBL] [Abstract][Full Text] [Related]
3. Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard.
Dalbeth N; Schumacher HR; Fransen J; Neogi T; Jansen TL; Brown M; Louthrenoo W; Vazquez-Mellado J; Eliseev M; McCarthy G; Stamp LK; Perez-Ruiz F; Sivera F; Ea HK; Gerritsen M; Scire CA; Cavagna L; Lin C; Chou YY; Tausche AK; da Rocha Castelar-Pinheiro G; Janssen M; Chen JH; Cimmino MA; Uhlig T; Taylor WJ
Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1894-1898. PubMed ID: 27014846
[TBL] [Abstract][Full Text] [Related]
4. Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A case-control study using data from the UK Biobank.
Sandoval-Plata G; Morgan K; Abhishek A
Rheumatol Int; 2022 Sep; 42(9):1617-1622. PubMed ID: 35633389
[TBL] [Abstract][Full Text] [Related]
5. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
[TBL] [Abstract][Full Text] [Related]
6. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
[TBL] [Abstract][Full Text] [Related]
7. Mediation analysis to understand genetic relationships between habitual coffee intake and gout.
Hutton J; Fatima T; Major TJ; Topless R; Stamp LK; Merriman TR; Dalbeth N
Arthritis Res Ther; 2018 Jul; 20(1):135. PubMed ID: 29976226
[TBL] [Abstract][Full Text] [Related]
8. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
Juraschek SP; Kovell LC; Miller ER; Gelber AC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
[TBL] [Abstract][Full Text] [Related]
9. The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect.
Topless RKG; Major TJ; Florez JC; Hirschhorn JN; Cadzow M; Dalbeth N; Stamp LK; Wilcox PL; Reynolds RJ; Cole JB; Merriman TR
Arthritis Res Ther; 2021 Mar; 23(1):75. PubMed ID: 33663556
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016.
Tsoi MF; Chung MH; Cheung BMY; Lau CS; Cheung TT
Arthritis Res Ther; 2020 Sep; 22(1):204. PubMed ID: 32887668
[TBL] [Abstract][Full Text] [Related]
12. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
13. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
[TBL] [Abstract][Full Text] [Related]
14. Urate-lowering treatment and risk of total joint replacement in patients with gout.
Kuo CF; Chou IJ; See LC; Chen JS; Yu KH; Luo SF; Hsieh AH; Zhang W; Doherty M
Rheumatology (Oxford); 2018 Dec; 57(12):2129-2139. PubMed ID: 30060176
[TBL] [Abstract][Full Text] [Related]
15. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
16. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus.
Zaidi F; Narang RK; Phipps-Green A; Gamble GG; Tausche AK; So A; Riches P; Andres M; Perez-Ruiz F; Doherty M; Janssen M; Joosten LAB; Jansen TL; Kurreeman F; Torres RJ; McCarthy GM; Miner JN; Stamp LK; Merriman TR; Dalbeth N
Rheumatology (Oxford); 2020 Sep; 59(9):2544-2549. PubMed ID: 31998961
[TBL] [Abstract][Full Text] [Related]
17. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with initiation and persistence of urate-lowering therapy.
Dehlin M; Ekström EH; Petzold M; Strömberg U; Telg G; Jacobsson LT
Arthritis Res Ther; 2017 Jan; 19(1):6. PubMed ID: 28095891
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
[No Abstract] [Full Text] [Related]
20. The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
Zhang X; Tang Y; Wang M; Wang D; Li Q
Clin Rheumatol; 2021 Feb; 40(2):701-710. PubMed ID: 32562072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
